TRANSVAC Funding of SPORCOVAX, SporeGen's Mucosal Vaccine to COVID-19

  • June 11, 2020
  • SporeGen

SporeGen has just received notification to evaluate its candidate mucosal vaccine, SPORCOVAX, to COVID-19 in collaboration with the Helmholtz Centre for Infection Research (Germany) and funded by TRANSVAC a collaborative infrastructure project under the umbrella of the European Vaccine Initiative (EVI).

The SporeGen approach uses spores of a proprietary strain of B. subtilis that have been engineered to express SARS-Cov-2 antigens.